About OncoQuest

About company

The Company has assembled several bioactive technologies, including human and xenotypic monoclonal antibodies of the IgG and IgE class that can induce tumor specific immunity and enhance clinical outcome. Several of the lead components have clinical track records and extensive development dossiers that can be exploited to be integral to combinatorial immunooncology treatment strategies.